Cardium Therapeutics' (NYSE MKT: CXM) Generx® product candidate (alferminogene tadenovec, Ad5FGF-4) is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease. Generx is designed to stimulate the growth of supplemental collateral blood vessels in the heart in order to enhance myocardial blood flow in patients who have insufficient blood flow due to atherosclerotic plaque restricting flow in the coronary arteries that supply the heart. Generx has progressed through four randomized, placebo-controlled clinical studies at over 100 medical centers in the United States and Western Europe that have enrolled over 650 patients. Generx is designed as a disease-modifying regenerative medicine therapeutic that can elicit structural and physiologic changes in the heart (the growth of new collateral blood vessels) following a one-time intracoronary administration from a standard cardiac infusion catheter. In contrast, traditional drug therapies such as nitrates and beta blockers provide transient symptomatic relief of anginal chest pain without changing the underlying disease. In the United States, anti-anginal drugs have traditionally been registered by the FDA based on improvements in exercise treadmill tolerance testing (ETT), which can confirm short-term symptomatic relief of angina. Based on the disease-modifying nature of Generx, Cardium believes that a more objective and appropriate measure to assess the effectiveness of angiogenic therapy is cardiac perfusion, the actual blood flow in the heart under stress using SPECT imaging (single photon emission computed tomography) or another advanced imaging technique. Cardiac perfusion directly shows and quantifies improvements in the underlying physiologic condition, i.e. insufficient blood flow under stress. Generx is currently being developed for international markets outside United States as a treatment alternative for patients who may not have access to or may not be candidates for costly and invasive surgical revascularization procedures, such as coronary artery bypass surgery and angioplasty/stents. Learn more at: http://cardiumthx.com/generx.html

1. 15-Jan-13
Product &
Technology
Overview
 2013 Cardium Therapeutics, Inc.
Generx ®
Angiogenic Therapy
Regenerative Medicine for
Interventional Cardiology DNA-Based
Non-Surgical
1 Angiogenic Therapy

2. Forward Looking Statements
This presentation may contain forward-looking statements, including
comments concerning clinical trials and product development programs,
evaluation of potential opportunities, the level of corporate expenditures,
the assessment of Cardium’s technology by potential corporate partners,
capital market conditions, timing of events, cash consumption and other
subjects. Actual results could differ materially from these forward-looking
statements for many reasons, including the risks described under "Risk
Factors" in the Company’s Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q as filed with the Securities and Exchange
Commission. No guarantee about future results, performance or
achievements can be made. Neither Cardium nor its agents intend to
 2013 Cardium Therapeutics, Inc.
update any of the forward-looking statements after the date of this
presentation to conform them to actual results or to changes in
expectations.
2

3. Scientific Overview and Therapeutic Rationale
DNA-Based Cardiovascular Therapeutics
 New regenerative  Ischemia (coronary heart
medicine biological disease) is an important
tools for interventional precursor for effective
cardiology growth factor DNA-based
therapy
 Leverages the
healing power of  Designed to stimulate
cardiac plasticity microvascular cardiac
angiogenesis
 Proprietary, catheter-
based intracoronary  Driven by upstream
delivery approach regulatory gene (FGF-4)
during an angiographic that stimulates a cascade
procedure of other important growth
factors
 One-time non-surgical
 2013 Cardium Therapeutics, Inc.
treatment  First DNA-based biologic
to advance to U.S. FDA
 DNA transgene Phase 3 (with fast track
delivery and CAR status) and Registration /
receptor-based Generx [Ad5FGF-4] Phase 3 Study in Russia
preferential cardiac
uptake
3

4. Generx® Highlights
 Generx [Ad5FGF-4] (CardioNovo® trade name in Russia) represents a new therapeutic class of
regenerative medicine DNA-based biologics for interventional cardiology that is designed to
stimulate the natural growth of microvascular circulation for a condition termed cardiac
microvascular insufficiency (CMI) for patients with myocardial ischemia and symptomatic angina
pectoris due to advanced coronary disease. Generx is administered one-time, using a standard
balloon cardiac catheter.
 Generx is initially being currently developed, in markets outside the U.S., as treatment alternative
for patients who may not have access to costly and invasive advanced mechanical
revascularization procedures, including coronary artery bypass surgery and angioplasty/stents, or
may no longer be optimal candidates for these procedures.
 Ad5FGF-4 has been evaluated in four clinical studies in North America and Western Europe at
over 100 medical centers with over 650 patients participating in these studies. Data from the
clinical studies have been published in leading peer reviewed medical journals.
 The product appears safe and capable of improving microvascular circulation
in certain patients, as measured by SPECT imaging, and improvements using
standard ETT assessments.
 2013 Cardium Therapeutics, Inc.
 An independent 10-year clinical study (n=845) by Swiss researchers, published in the American
Heart Association’s journal Circulation, have reported that patients with high levels of collateral
circulation in the heart have a statistically significant mortality advantage when compared to
patients with low collateral flow.
 Generx was cleared by the FDA to initiate the AWARE Phase 3 clinical study (with Fast Track
status) by the FDA, for certain refractory patients. Ad5FGF-4 is the only DNA-based
cardiovascular biologic to be cleared for Phase 3 clinical study by the FDA.
4

5. Generx® Highlights
 The AWARE clinical trial was inactivated by Cardium based on economic
considerations due to the patient recruitment challenges for a small targeted
population group in the U.S. where by-pass surgery and angioplasty are
commonly available to patients of all ages.
 Generx is now being evaluated in a Phase 3 / registration study (the Aspire Study) for 100 patients
with advanced coronary artery disease at up to six major medical centers in the Russian
Federation in connection with a commercialization plan covering the marketing and sale of Generx
in Russia. Ad5FGF-4 will be marketed and sold in Russia under the trade name “Cardionovo.”
 Recent discoveries from Cardium-sponsored preclinical studies at Emory University showed that
induced transient ischemia (i.e. balloon catheter-based occlusion/ reperfusion as in an ordinary
angioplasty, but at lower pressure) substantially increases Generx’s DNA vector’s transfection
efficiency to heart muscle cells. These new findings offer the opportunity to further enhance
angiogenic response and lower response variability in patients.
 These findings have now been integrated into the Russian-based
ASPIRE clinical study protocol.
 A senior group of current Cardium physicians and business executives have worked on the
 2013 Cardium Therapeutics, Inc.
Generx research and development effort from the initial development (1996) to the present.
 During the Generx development cycle, over $250 million has been invested in the product
formulation, manufacturing and clinical study by Collateral, Schering and Cardium.
 As a DNA-based bio-reactor manufactured product, Generx is projected to have favorable gross
margins and offers the potential to generate substantial revenue in large markets with coronary
artery disease.
5

6. Generx®: Historical Perspective
Collateral Schering AG Cardium Commercial
Therapeutics As Strategic Partner
Therapeutics International
(NASDAQ) with Collateral Formed to Development
Therapeutics Acquire Activities
University of Technology from
Schering Acquires
California Schering / Bayer
Collateral in 2002 Russia
San Diego FDA Phase 3 Clearance
for $160 Million
with Fast Track Status Brazil
Discovery, Licensing & Phase 3 Clearance India
Phase 1/2 to
and Initial for Registration Study
Phase 2b/3 in Russia
Preclinical Studies
 2013 Cardium Therapeutics, Inc.
1996 1997 - 2005 2005 - Present Current Status
6

7. Developing new and
innovative, cost-effective
advanced care for coronary
heart disease patients in
international markets
 2013 Cardium Therapeutics, Inc.
Generx Cardio Chant
7

8. Generx® [Ad5FGF-4]
Clinical & Commercial Development Activities
Cardium Innovations
• Expanded target coronary
artery disease patient
population
AGENT 1–4 • Established new quantitative ASPIRE
primary efficacy endpoint using
Phases 1 & 2/3 SPECT imaging Phase 3
Clinical Studies Clinical Study
• New balloon catheter-based
delivery techniques to leverage
Treatment: Stable Cardium’s transient ischemia Condition: Cardiac
discoveries to boost cell Microvascular Insufficiency
Angina for Patients with
transfection for Patients with Myocardial
“Refractory” Coronary Ischemia Due to Coronary
• Developed new “bio-assay”
Artery Disease production batch release assay Artery Disease
that measures angiogenic
 2013 Cardium Therapeutics, Inc.
Primary Endpoint: response to Generx Primary Endpoint:
ETT Improvement • Five-year real-time product RPDS Improvement as
stability (at -70°C) confirmed Measured by SPECT
650 Patients at
• Simplified and standardized
100 Medical Centers new cath lab product 100 Patients
preparation techniques
8

9. Generx® [Ad5FGF-4]
Product Focus for Russian Federation
Generx is being developed to promote the growth of microvascular circulation in the heart. It is
administered by a cardiologist through a cardiac catheter during an outpatient procedure.
The product is a new treatment option for a condition termed Cardiac Microvascular
Insufficiency (CMI) in patients with myocardial ischemia and symptomatic angina pectoris
due to coronary artery disease, for such patients that have limited access to advanced
medical care including coronary angioplasty and stents as well as coronary artery by-pass
surgery, and patients who are not optimal candidates for those procedures.
A long-term study (n = 845) has shown that patients with a higher collateral blood flow index may
have an improved mortality benefit when compared to patients with a relatively lower collateral
blood flow index.
Selected Health Statistics Benchmarks
United Russian
 2013 Cardium Therapeutics, Inc.
Demographic Metrics
States Federation
Average Life Expectancy - Males 76 64
Cardiovascular Death Rates per 100,000 80 297
9

10. CardioNovo®: Russian Federation
Phase 3 Registration Study
International Markets
Elements (Initially Russian Federation)
(ASPIRE)
CardioNovo [Ad5FGF-4]
Product
(alferminogene tadenovec)
RHA Cleared Phase 3 /
Clinical Status
Registration Study
100 Men & Women
Multi-Center, Randomized,
Clinical Study Population
Controlled Parallel-Group
Patient Population
Myocardial Ischemia as a
Treatment Option for Patients
Medical Indication
Considering Angioplasty /
 2013 Cardium Therapeutics, Inc.
Stents & Bypass Surgery
Improvement in Reversible
Clinical Endpoint Perfusion Deficit Based on
SPECT Imaging
Clinical Study Status Initiated 2012
10

11. Generx ®
[Ad5FGF-4]
DNA-Based Angiogenic Therapy
Interventional cardiology-focused product candidate that is being developed for a medical
condition termed Cardiac Microvascular Insufficiency (CMI) in patients with myocardial
ischemia and symptomatic chronic stable angina pectoris due to coronary artery disease.
 2013 Cardium Therapeutics, Inc.
Patients with CMI have had an insufficient angiogenic response to their current disease
state and may benefit from a therapy to biologically enhance cardiac perfusion through the
facilitation of collateral vessel formulation.
This condition is diagnosed by SPECT imaging, and other catheter-based diagnostic
techniques.
11

12. Generx® Pioneering
DNA-Based Regenerative Medicine
DNA-based therapy is designed to
enable a patient’s own cells to
produce a therapeutic protein directly
where it is needed in the body. The
 2013 Cardium Therapeutics, Inc.
Generx product candidate is designed
to induce localized angiogenic growth
factor production following its one-
time delivery to stimulate the growth
of microvascular circulation.
12

13.  2013 Cardium Therapeutics, Inc.
13
Cardiovascular Angiogenesis

14. Coronary Artery Disease
Natural Disease-Induced Angiogenic Vascularization
 2013 Cardium Therapeutics, Inc.
OFF ON
14

15. Beneficial Effects of a
Disease-Induced
Angiogenic Vascularization
Summary Research
“A well-functioning coronary
collateral circulation saves lives in
patients with chronic stable
coronary artery disease.”
 2013 Cardium Therapeutics, Inc.
From Meier et al. Circulation 2007; 116:975-83.
15

16. Generx® Late-Stage Clinical Development
 2013 Cardium Therapeutics, Inc.
16

17. Generx® Revolutionary Alternative
Therapy for Heart Disease
Coronary Artery Non-Surgical
Bypass Graft Cardiovascular
Surgery Gene Therapy
Objective
 2013 Cardium Therapeutics, Inc.
17

18. Generx® Leveraging the Power of Biology
This illustration utilizes computer
models of DNA-based on data
generated by x-ray crystallography, a
technique for determining the structure
 2013 Cardium Therapeutics, Inc.
of a molecular sample, together with a
portion of the DNA sequence of Generx
(Ad5FGF-4), Cardium’s lead clinical
product candidate.
Digital illustration of DNA.
18

19. Technology Platform:
Non-Surgical DNA-Based Angiogenic Therapy
Methods of
Intracoronary
DNA-Based
Angiogenic
Therapy
X Adenovirus
DNA-Based
Manufacturing Delivery (Ad5)
Know-How
& Expertise Angiogenic
Growth Factor
(FGF-4)
 2013 Cardium Therapeutics, Inc.
Generx® [Ad5FGF-4]
(alferminogene tadenovec)
19

20. Generx®
(alferminogene tadenovec)
DNA-Based
Adenovector Cassette
 Demonstrated CV Safety
Database with FDA
 Established FDA
Manufacturing Standards
 High Cardiac Transfection
Levels due to a Binding
Affinity with CAR Receptors
and Enhanced by Ischemia
 Transient Expression - -
Does Not Integrate into
Adenovector construct Host Genome
Carries the FGF-4 Gene
for Cardiac Delivery  Manufacturing in High Titer
 2013 Cardium Therapeutics, Inc.
 Easily Manipulated
Research Studies: Coronary
Intracoronary Administration Extraction Rate
 Relatively Low Cytotoxity
Pre-Clinical Porcine Study  Mutagenesis Improbable
98% (mean)
Giordano et al. Nat Med 1996;2:(5):534
 Very Favorable
Phase 1/2 Clinical Study – AGENT Trial Manufacturing Cost
87% (median)
Grines et al. Circulation 2002;105:1291
20

21. Generx® FGF-4 Gene
 Regulates angiogenesis
 Signal peptide – secreted FGF protein
 Binds to extracellular matrix proteins
 Abundant FGF-4 receptors found in cardiac tissue
 Upstream growth factor that can recruit and
stimulate responses in downstream target cells
 2013 Cardium Therapeutics, Inc.
 Appears to require ischemia induced
co-factors to augment the angiogenesis process
21

22. Generx Dose Response Bioactivity Assay
Visualization of the Angiogenic Process
by Endothelial Tube Formation
1ng/mL 2ng/mL 4ng/mL 8ng/mL
Representative Images (T=13.5 days) of rhFGF-4 stimulation of angiogenic networks in the Essen BioScience HUVEC Tube
Formation Assay. E, 1ng/mL rhFGF-4 induced HUVEC clustering as well as a small amount of tube formation. F, 2ng/mL rhFGF-4 induced
clusters and tube formation. G, 4ng/mL rhFGF-4 initiated HUVEC differentiation into longer tubes and more complex networks, as observed by
the increase in branching. H, 8ng/mL rhFGF-4 stimulate significant tube and network formation.
 2013 Cardium Therapeutics, Inc.
22

23. Generx® Understanding the
Beauty of Cardiac Physiology
Microvascular
Pathways
When infused into the coronary arteries
using a non-surgical cardiac catheter, the
 2013 Cardium Therapeutics, Inc.
Generx product candidate travels through
the coronary microvascular circulation into
the small caliber capillaries where it is
believed to be taken up by the myocardium.
Colored magnification: x3000 at 6x7cm size.
23

24. Generx [Ad5FGF-4]
Proprietary Intracoronary Administration of
DNA-Based Cardiovascular Growth Factor Therapeutic
 Non-surgical delivery by intracoronary administration by
interventional cardiologist during an angiogram procedure
 2013 Cardium Therapeutics, Inc.
 Utilizes standard balloon catheter which can be easily
integrated into diagnostic angiogram procedures or with other
percutaneous coronary interventions
 New induced transient ischemia / reperfusion techniques are
designed to enhance DNA uptake and expression in the heart
 40% administered to right coronary circulation and
60% to left coronary circulation
24

25. Generx® [Ad5FGF-4]
Catheter-Based Enhanced Angiogenic
Intracoronary Delivery Microvascular Circulation
 2013 Cardium Therapeutics, Inc.
25

26. The Therapeutic Process of
Cardiac Microvascular Angiogenesis
Generx has been evaluated in studies of over 650 patients (including 450
Generx-treated patients) in four multi-center, double-blind, placebo-controlled SPECT Imaging
clinical studies at 100 medical centers. Generx is the most clinically advanced
DNA-based cardiovascular angiogenic growth factor therapeutic in the world.
One-Time Treatment
DNA-Based Delivery
 2013 Cardium Therapeutics, Inc.
Generx [Ad5FGF-4]
(alferminogene tadenovec)
Angiogenic Response
AGENT-2 - Representative Generx-treated patient: 77%
improvement in cardiac perfusion at 8 weeks equivalent
to bypass surgery and PCI (angioplasty/stenting) at one year.
26

27. AGENT 2: Primary Endpoint SPECT Imaging Angiogenic
Mechanism of Action Study
Change in Reversible Perfusion Defect
8 Weeks
Mean Reduction in RPDS (%)
6
5
4
3
2 p=0.14
1
p<0.05*
 2013 Cardium Therapeutics, Inc.
0
Placebo 10e10 vp
n=17/16 n=35
* Excludes one extreme placebo outlier
27

28. Generx® [Ad5FGF-4] Clinical Studies
Clinical Number
Region / Patient Clinical
Year Study Name Study Patients
County Status Endpoint
Phase Recruited
Phase 1/2
Class 2 – 3 Exercise
1999 AGENT-1 U.S. Dose finding 79
Angina Treadmill Time
& safety
Phase 2a
9% Reversible
AGENT-2 Mechanism SPECT
2001 North America Reperfusion 52
of Action Imaging
Defect
Study
AGENT-3 Class 2 – 4 Exercise
2004 North America Phase 2b/3 300
Angina Treadmill Time
Western
Class 2 – 4 Exercise
2004 AGENT-4 Europe & Phase 2b/3 252
Angina Treadmill Time
South America
Exercise
Class 3 – 4 Treadmill Time
 2013 Cardium Therapeutics, Inc.
U.S. Beta
2008 AWARE U.S. Phase 3 Angina (Time to ST
Tested
Segment
Depression)
Phase 3
Russian 9% Reversible SPECT
2011 ASPIRE Registration 100
Federation Perfusion Defect Imaging
Study
TOTAL 783
28

29. Generx® Patient Pioneers
Marilyn L. was a trial participant in
the AGENT-3 clinical trial. She
received a one-time treatment of
 2013 Cardium Therapeutics, Inc.
Generx, our DNA-based angiogenic
product candidate for patients with
recurrent angina due to coronary
artery disease.
29

30. Generx®
Key Peer-Reviewed
Scientific & Medical Journals
 2013 Cardium Therapeutics, Inc.
Pre-Clinical AGENT-1 AGENT-2
Nature Circulation Journal of American
Medicine (American Heart College of Cardiology
Association Journal)
30

31. Generx®
AGENT 3 & 4
Summary Research
“We found a significant, gender-
specific beneficial effect of
Ad5FGF-4 on total ETT time, time to
1 mm ST-segment depression, time
to angina and CCS Class in women.
This is the first clinical report of a
gender difference in response to
cardiac angiogenic therapy.”
“The potential importance
of the observed gender-specific
angiogenic response on the
clinical treatment of refractory
 2013 Cardium Therapeutics, Inc.
angina is substantial and
deserves further investigation.”
JACC
September 11, 2007
31

32. GENERX AGENT-2
PHASE 2A STUDY
CLINICAL EFFICACY USING SPECT
77%
Improvement
AGENT-2
Journal of
 2013 Cardium Therapeutics, Inc.
American College
of Cardiology
Generx-Treated Patient Demonstrating
Enhanced Cardiac Perfusion
(n=52 / 88% men)
32

33. AGENT 2 - Comparison of SPECT Results to
Revascularization and Medical Therapy
Coronary Generx AGENT-2
Medical
Parameter Revascular-
Therapy
ization Placebo 1x1010 vp
Number
83 206 17 35
of Patients
Age 66 11 68 10 57 9 59 8
Stress defect
18 11 16 10 20 8 20 9
extent (%)
 2013 Cardium Therapeutics, Inc.
Reduction of
reversible -5 12 -0.8 7 -0.8 6 -4 6
defect (%)
From Berman DS, et al.
J of Nuclear Cardiol, 2001; 4:428-437
33

34. Generx AGENT 3 & 4 Clinical Studies
Clinical Efficacy Using ETT
Pooled-Analysis: Protocol-Specified Gender-Based Subgroup
12 weeks 6 months
Women
n=76
Placebo 109 vp 1010 vp Placebo 109 vp 1010 vp
Exercise -4 60* 69* 7 75* 83*
Duration
(seconds
percentage ) (-1%) (16%) (23%) (2%) (20%) (28%)
50 111 86 55 157* 94
Angina Onset
(seconds
percentage )
 2013 Cardium Therapeutics, Inc.
(26%) (52%) (46%) (28%) (73%) (48%)
Time to 1mm ST 13 50 63* 14 59* 86*
Segment 
(seconds
percentage ) (4%) (16%) (27%) (5%) (19%) (36%)
* < 0.05
34

35. AGENT 3/4 Clinical Studies:
Concordance of Results from Prespecified Pooled
Analysis of Gender-Based Subgroup
Generx Ad5FGF-4
Women
Time Point
n=76
1x109 vp 1x1010 vp
12 Weeks p=0.032 p=0.002
ETT Duration
6 Months p=0.042 p=0.009
12 Weeks NS (0.216) p=0.031
Time to ECG Ischemia
6 Months p=0.036 p=0.011
12 Weeks NS (0.146) NS (0.125)
Time to Angina
6 Months p=0.003 NS (0.094)
 2013 Cardium Therapeutics, Inc.
12 Weeks NS (0.222) p=0.014
CCS Class Improvement 6 Months NS (0.341) p=0.042
12 Months p=0.038 p=0.006
NS=Not Significant
35

36. Effect of Chronic Angina Treatment with Ranexa
and Single Intracoronary Administration of
Generx (Ad5FGF-4) on ETT Duration at 12 Weeks
(Difference from Placebo)
100
* ETT
* P > 0.05 vs. placebo
Mean change from Baseline (sec)
75
Generx
50 One Time
Non-Surgical
Angiogenic
Therapy *
 2013 Cardium Therapeutics, Inc.
25
Ranexa
Chronic
Anti-Anginal Drug
1000 mg Daily
0
Baseline ETT (sec): 300 Baseline ETT (sec): 470
% increase + 25% % increase + 5%
(n = 30) (n = 255)
36

37. Beneficial Effects of Natural Disease-Induced Collateral Vessels
10-Year Follow-up in Patients with Coronary Heart Disease
%
CARDIAC DEATHS:
Cumulative Survival Rate
10 year follow-up
(n = 845)
High Flow:
5 (2%) Deaths
Low Flow:
37 (6%) Deaths
(low collateral flow)
 2013 Cardium Therapeutics, Inc.
67% ↓
(high collateral flow) Cardiac Deaths
Time of Follow-up (months)
From Meier et al. Circulation 2007; 116:975-83.
37

38. Generx®: Current Global Clinical Study Status
International Markets
U.S. Market
Elements (Initially Russian Federation)
(AWARE)
(ASPIRE)
Generx® [Ad5FGF-4] CardioNovo [Ad5FGF-4]
Product (alferminogene tadenovec) (alferminogene tadenovec)
FDA Clearance Phase 3 RHA Cleared Phase 3 /
Clinical Status (with Fast Track Status) Registration Study
100 Men & Women
300 Women Multi-Center,
Multi-Center, Randomized,
Clinical Study Population Randomized, Placebo-
Controlled Parallel-Group
Controlled Patient Population
Patient Population
Anti-Angina for Refractory Myocardial Ischemia as a
Patients who are not Optimal Treatment Option for Patients
Proposed Medical Indication Candidates for Angioplasty / Considering Angioplasty /
Stents & Bypass Surgery Stents & Bypass Surgery
 2013 Cardium Therapeutics, Inc.
Improvement in Reversible
Improvement in Exercise
Clinical Endpoint Time Based on Treadmill
Perfusion Deficit Based on
SPECT Imaging
Pending Completion
Clinical Study Status Initiated 2012
of International Studies
38

39. Clinical Efficacy Measures
ETT SPECT
 2013 Cardium Therapeutics, Inc.
Exercise Treadmill Single Photon Emission Computed
Stress Test Tomography Stress Test
[United States Efficacy Measure] [Russian Federation Efficacy Measure]
39

40.  2013 Cardium Therapeutics, Inc.
40
Therapeutic Comparison

41. Potential Therapeutic Positioning:
Generx® / Cardionovo®
(PTCA)
Percutaneous
Traditional Transluminal
Drug Coronary
Therapy Angioplasty
& Stents
Coronary
Artery
Disease
Generx®
(CABG)
Non-Surgical
 2013 Cardium Therapeutics, Inc.
Coronary DNA-Based
Artery Bypass Angiogenic
Surgery Therapy
41

42. Potential Generx® [Ad5FGF-4] Medical Indications
Based on Clinical Study Design
 Patients with Cardiac Microvascular  Patients who have recurrent ischemic
Insufficiency (CMI) with myocardial episodes under observation during or
ischemia and stable angina pectoris after an acute myocardial infarction
due to coronary artery disease
 Patients with ischemic heart disease
 Patients with stable angina pectoris who who desire or need revascularization
have already had coronary bypass surgery but do not have access to coronary
but have persistent angina bypass surgery or angioplasty
 Patients who have had angioplasty  Patients who would benefit from
or stenting but who continue to have revascularization (as above) but who
symptoms of myocardial ischemia are at high risk for invasive procedures
 Patients who are undergoing angioplasty or who do not want invasive procedures
in whom revascularization is judged to be
incomplete  Patients undergoing cardiac
catheterization at a facility that does
 Patients who are undergoing angioplasty not perform angioplasty who need
with at risk myocardium downstream revascularization
 2013 Cardium Therapeutics, Inc.
from a coronary stenosis that can not
be adequately dilated  Patients undergoing routine diagnostic
cardiac catheterization for coronary artery
 Patients who have evidence of silent disease who have any of the indications
ischemia, as indicated by intermittent above. Generx may obviate the need for
electrocardiographic changes during subsequent referral for bypass surgery or
ambulatory monitoring, or ventricular for angioplasty
contraction abnormalities during stress.
Silent ischemia is a risk factor for
subsequent major cardiac events
42

43. Generx® Potential Economic Opportunity
Target Revenue per Dose
Unit Volume
Opportunity per Level I Level II Level III
Economic Region $2,000 / dose $3,000 / dose $4,000 / dose
50,000 doses $100 Million $150 Million $200 Million
100,000 doses $200 Million $300 Million $400 Million
150,000 doses $300 Million $450 Million $600 Million
 2013 Cardium Therapeutics, Inc.
200,000 doses $400 Million $600 Million $800 Million
43

44.  2013 Cardium Therapeutics, Inc.
 2013 Cardium Therapeutics, Inc.
44